Eran Rotem

CIK 1423145 · Deputy CEO and CFO · last filed 2026-09-08

Eran Rotem is a Deputy CEO and CFO who has filed 4 SEC Form 4 insider transactions across 2 companies since 2008. The most recent filing, for CLGN, was dated Sep 8, 2026. Current disclosed insider exposure totals $1.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$1.85M

Companies

Total Filings

Lifetime Open-Market Net

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address

2533 WINDGUARD CIRCLE
SUITE 101
WESLEY CHAPEL, FL 33544

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
CLGN	Deputy CEO and CFO	516,372	$3.59	$1.85M	$0	1	2026-09-08
Laxai Pharma Ltd (HCTL) Delisted	Chief Financial Officer	420,000	—	—	$0	1	2008-01-11

Recent Filings

4 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-09-08	CLGN	Grant (A)	+510,372	$0	EDGAR
2008-03-26	—	Exer (M)	+117,000	$73.6K
2008-03-19	—	Exer (M)	+117,000	$73.6K
2008-01-11	Laxai Pharma Ltd (HCTL) Delisted	Grant (A)	+400,000	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.